42 Bio is a new spin-off company developing and commercializing biomedical technologies from our laboratories at the University of Florida.
42Bio develops novel and unique technologies that address existing barriers to research and clinical translation in tissue engineering and regenerative medicine.
We have a strong and growing patent portfolio in these areas, and have launched several products with more in the pipeline.